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Available online 28 June 2019Background: The transcription factor Nrf2 is a master regulator of antioxidant response. While Nrf2 activation
may counter increasing oxidative stress in aging, its activation in cancer can promote cancer progression andme-
tastasis, and confer resistance to chemotherapy and radiotherapy. Thus, Nrf2 has been considered as a key phar-
macological target. Unfortunately, there are no specific Nrf2 inhibitors for therapeutic application. Moreover,
high Nrf2 activity in many tumors without Keap1 or Nrf2 mutations suggests that alternative mechanisms of
Nrf2 regulation exist.
Methods: Interaction of FAM129B with Keap1 is demonstrated by immunofluorescence, colocalization, co-
immunoprecipitation andmammalian two-hybrid assay. Antioxidative function of FAM129B is analyzed bymea-
suring ROS levels with DCF/flow cytometry, Nrf2 activation using luciferase reporter assay and determination of
downstreamgene expression by qPCR andwester blotting. Impact of FAM129B on in vivo chemosensitivity is ex-
amined in mice bearing breast and colon cancer xenografts. The clinical relevance of FAM129B is assessed by
qPCR in breast cancer samples and data mining of publicly available databases.
Findings:We have demonstrated that FAM129B in cancer promotes Nrf2 activity by reducing its ubiquitination
through competition with Nrf2 for Keap1 binding via its DLG and ETGE motifs. In addition, FAM129B reduces
chemosensitivity by augmenting Nrf2 antioxidative signaling and confers poor prognosis in breast and lung can-
cer.
Interpretation: These findings demonstrate the important role of FAM129B in Nrf2 activation and antioxidative
response, and identify FMA129B as a potential therapeutic target.
Fund: The Chang Gung Medical Foundation (Taiwan) and the Ministry of Science and Technology (Taiwan).
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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TheNrf2 (Nuclear factor-erythroid 2-related factor 2)-Keap1 (Kelch-
like ECH-associated protein 1) system is a key cellular defense
mechanism against oxidative stress. The key function of the transcrip-
tion factor Nrf2 is to govern the cellular antioxidant response by
transcriptionally activate several cytoprotective genes to protect cell
from the effect of oxidative stress [1]. Under basal conditions, Nrf2 is
constitutively degraded through the ubiquitin-proteasome pathwayranslational Cancer Research,
g University, Taoyuan 33305,
. This is an open access article undervia interaction with Keap1, a substrate scaffold for Cul3-containing E3
ubiquitin ligase [2,3]. Under conditions of oxidative stress, Nrf2-Keap1
interaction is disrupted by modification of cysteine residues of Keap1,
such as C151, C273, or C288, causing a conformational change that
may affect its ideal binding with Cul3 or Nrf2 and resulting in dimin-
ished Nrf2 ubiquitination [4]. The consequent stabilization of Nrf2 al-
lows its translocates to the nucleus, where it induces the transcription
of numerous genes involved in cell defense, including antioxidants,
drug-metabolizing enzymes, and drug efflux transporters by binding
to the antioxidant response elements (AREs) in their regulatory regions
[5,6].
The activation of Nrf2 helps normal cells to endure oxidative stresses
and maintain the redox homeostasis. Under physiological conditions,
Nrf2 signaling is turned on by the presence of stressors and is rapidlythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Nrf2-Keap1 system is a key cellular defense mechanism against
oxidative stress. Somaticmutations ofNrf2 or Keap1 contributing
to Nrf2 hyperactivation have been reported in many cancers.
However, few studies address the mechanisms of Nrf2 activation
without such genetic mutations. Thus, it is imperative to explore
alternative regulatory mechanisms that govern the Nrf2 activa-
tion, which may offer novel strategies for cancer treatment.
Added value of this study
FAM129B competes with Nrf2 for binding to Kelch domain of
Keap1 via its DLG and ETGE motifs. FAM129B can stabilize Nrf2
to drive downstream antioxidant genes, confer resistance to oxi-
dant injury and chemotherapeutics. Clinically, higher expression
of FAM129B correlates with poorer outcome in cancer by data
mining. Examination of breast cancer samples shows high
FAM129B expression to be an independent predictor of tumor
recurrence.
Implications of all available evidence
This study shows that expression of FAM129B in cancer pro-
motes Nrf2 activity by reducing its degradation through binding
to Keap1. It provides an alternative mechanism that regulates
the Nrf2 activation and anti-oxidative response. These findings
elucidate the mechanistic underpinnings on how FAM129B re-
duces chemosensitivity, and identify FAM129B as a new antioxi-
dant molecule, a potential cancer therapeutic target and a poor
prognosis factor for cancer.
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ditions, the tight regulation of Nrf2may be lost, resulting in constitutive
activation of Nrf2 which confers a survival advantage to cancer cells
under adverse conditions [7]. Several studies have indicated that aber-
rant activation of Nrf2 is beneficial to cancer cells because Nrf2 down-
stream genes play crucial roles in cell survival, and tumor promotion
[8–10]. Recent cancer genomic studies have revealed somaticmutations
of Nrf2 or Keap1 that disrupt Keap1-Nrf2 interaction in many cancers
[11–13], and are associated with resistance to chemotherapies. In addi-
tion tomutation, hypermethylation of the Keap1 promoter and amplifi-
cations of Nrf2 copy number can also promote Nrf2 activity in cancer
[14,15]. These findings indicate that Nrf2 hyperactivation protects can-
cer cells from excessive oxidative stress, chemotherapeutic agents, or
radiotherapy and therby promote their survival [7]. Interestingly, Nrf2
is hyperactivated in many tumors lacking genetic alterations in Nrf2
or Keap1, implying that alternative mechanisms of Nrf2 regulation
exist. In this study, we have identified FAM129B (Family with sequence
similarity 129,member B) as an alternative regulator for Nrf2 activation,
and may serve as a novel target for cancer treatment.
FAM129B, also known as Niban-like protein 1 or MINERVA, belongs
to a family of Niban proteins that includes FAM129A (also known as
Niban) and FAM129C (also known as Niban-like protein 2 or B-cell
novel protein 1). Although three members of this protein family share
some amino acid sequence identity, little is known about the function
or regulation of these proteins in any organism [16]. Interesting,
FAM129B is up-regulated in several type of human cancer, such as
breast, lung, colon, renal and endometrial cancers as well as hematopoi-
etic and central nervous system tumors [17,18]. The protein structure of
FAM129B contains a pleckstrin homology (pH) domain near the amino-
terminus and a proline-rich domain near the carboxyl-terminus, whichhas six serine residues that can be phosphorylated [16]. Recent studies
indicate that phosphorylation of FAM129B by EGFR at the Y593 residue
mediates Ras activation and that FAM129B phosphorylation by ERK1/2
promotes tumor cell invasion [16,19]. In addition, FAM129B knockdown
not only inhibits Wnt3A/β-catenin signaling-mediated expression of
AXIN2 but also accelerates TNFα-induced apoptosis, which can be re-
versed by co-transfection with recombinant FAM129B [20,21]. How-
ever, the detailed molecular mechanisms linking these findings on
FAM129B are largely unknown. In this report, we presentmolecular ev-
idence supporting the notion that FAM129B-dependent cell survival
under oxidative stress is mediated through stabilization of Nrf2 protein
by a mechanism involving competition between FAM129B and Nrf2 for
binding to Keap1. Importantly, we also demonstrate that the expression
of FAM129B correlates with adverse clinical outcome.
2. Materials and methods
2.1. Cell culture and chemicals
MDA-MB-231, Hs578T, and HCT116 were obtained from the
Bioresource Collection and Research Center (BCRC, Taiwan). H1299
and 293T cells were obtained from the ATCC. Cells were grown in
Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS. All
cells were cultured at 37 °Cwith 5% CO2. Cell lineswere routinely tested
to exclude mycoplasma contamination.
2.2. In silico prediction of binding of human Keap1 protein bind to FAM129B
through both DLG and ETGE motifs
In order to model the complex structures comprising the Kelch do-
main of human Keap1 and the peptide segments of FAM129B, the com-
plexmodelswhichwere searched fromProteinData Bank (http://www.
rcsb.org) reveal the molecular interactions between the mouse Keap1
and Nrf2 peptide segments containing DLG or ETGE motifs (PDB:
3WN7 and 1X2R, respectively) were provided as structural templates
for homology modeling. The sequence alignments among human
Kelch domain and its mouse homologs were performed using BLAST
[22]. The 3D structure of human Kelch domain and the complex struc-
tures binding with FAM129B segments were simulated using Modeller
v9.12 [23],with the functionsof theAUTOMODEL class in python scripts.
After energy optimization and refinement, the Discrete Optimized Pro-
tein Energy (DOPE) method [23] was used to select the best model
from the initially-generated models. The molecular interactions be-
tween Kelch domain and FAM129B peptide were analyzed and scored
by the HotLig [24]. The high-quality images of protein-peptide models
were rendered using UCSF Chimera [25]. The 2D schematic diagrams
for illustratingmolecular interactionswere generated using Ligplot [26].
2.3. In vivo studies in xenograft mouse models
Male severe combined immune-deficient (NOD/SCID) mice be-
tween 4 and 5 weeks of age were purchased from the National Labora-
tory Animal Center (NLAC), NARLabs. FAM129B expression in HCT116
was suppressed by transfection with the pooled three siRNAs targeting
FAM129B (HCT116/si-FAM129B); cells transfected with non-specific
control oligos served as a control (HCT116/si-Control). The si-
FAM129B and si-Control HCT116 cells were inoculated subcutaneously
1.5 × 106 cells) into the flank of the NOD/SCID mice. When the tumor
sizes reached about 100 mm3, the mice were randomly divided into
two groups and subjected to treatment with PBS or oxaliplatin
(7.5 mg/kg, intraperitoneally, every 4 days for 3 weeks) (n = 5 for
each group). The tumor volumes, calculated as length × width2 × 0.5,
were determined twice a week. At day 20 after injection of tumor
cells, the tumors were carefully removed, photographed and weighed.
Female severe combined immune-deficient (NSG) mice between 4
and 5 weeks of age were purchased from The Jackson Laboratory.
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tion with the pooled three siRNAs targeting FAM129B (MB-231/si-
FAM129B); cells transfected with non-specific control oligos served as
a control (MB-231/si-Control). The si-FAM129B and si-Control MB-
231 cells (1.5 × 106 cells) were injected into mammary fat pad of the
NSG mice. After 2 days, the mice were randomly divided into two
groups and subjected to treatment with PBS or oxaliplatin (20 mg/kg,
intraperitoneally, once) (n=4 for each group). The tumor volumes, cal-
culated as length ×width2 × 0.5, were determined twice a week. At day
35 after injection of tumor cells, the tumors were carefully removed,
photographed and weighed. All procedures were performed in compli-
ancewith the regulations of the Institutional Animal Care andUse Com-
mittee of Chang-Gung University.
2.4. Breast cancer patient samples
One hundred and twenty-six fresh primary breast cancer tumor and
adjacent normal tissue specimens were collected during surgical resec-
tions performed at the Tri-Service General Hospital (Taipei, Taiwan). In-
formed consentwas obtained from all subjects before their tissues were
deposited. The samples were fully encoded and used under a protocol
approved by the Institutional Review Board of the Human Subjects Re-
search Ethics Committee of the Tri-Service General Hospital and
Chang Gung Memorial Hospital (Taoyuan, Taiwan). The clinicopatho-
logic information is listed in Supplemental Table S1.
2.5. Small interfering RNAs (siRNAs) and plasmid transfection
siRNAs specifically targeting FAM129B and non-specific si-Control
RNAs were synthesized by MDBio. The sequences are shown in the
Key Resources Table. Transfection with the pooled three FAM129B
siRNAs listed in the table was performed with RNAiMAX
(ThermoFisher) according to the manufacturer's instructions.
Full length Keap1 and the five truncated Keap1 mutants shown in
the Key Resources Table were cloned into pACT vectors. Full length
FAM129B, Nrf2, and Keap1 were cloned into pBIND, pcDNA3.1 and
pFLAG-CMV2 vectors, respectively, using appropriate restriction en-
zyme digests. The numbered (or indicated) amino acids in DLG708 and
E718T719GE inwild-type FAM129Bwere replacedwith alanine, to gener-
ate DLA708- and A718A719GE-mutant FAM129B, respectively, using the
QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent) with
full length FAM129B-expressing plasmids as templates. Transfections
of plasmid DNAwere performedwith TransIT-2020 reagent (Mirus) ac-
cording to the manufacturer's instructions.
2.6. ROS detection
Cells were treated with 10 μM 2′,7′-dichlorofluorescein diacetate
(DCF-DA) for 30 min, following 2 washes with PBS. Reduced DCF-DA
can be oxidized and converted to fluorescent 2′,7′-dichlorofluorescein
(DCF) by intracellular ROS. Fluorescence signals were detected by flow
cytometry (Sony EC800 Analyzer). Totally, 10,000 cells were analyzed
per sample.
2.7. Western blot (WB) assay
Cells were washed with PBS and lysed in RIPA buffer containing NP-
40 and protease inhibitors (Roche). Total protein extracts (10–30 μg)
were separated on 4–12% NuPAGE (Invitrogen), and transferred to
PVDF membranes (Millipore, Bedford, MA, USA). The membranes
were incubated with primary antibodies at 4 °C overnight, followed by
alkaline phosphatase-conjugated secondary antibodies (Jackson
Immunoresearch Laboratories) for 1 h at room temperature. Then, the
membrane was scanned with a Typhoon9400 Variable Mode Imager
(GE Healthcare Life Sciences) to detect the fluorescent signals released
from catalyzed ECF substrate (GE Healthcare Life Sciences). The detailsfor the antibodies used in this study are provided in the Key Resources
Table. The results of western blots were quantified using ImageQuant
5.2 software (GE Healthcare Life Sciences).
2.8. Real-time PCR (RT-PCR)
Total RNA of breast cancer tissue was isolated using TRIzol reagent
(Invitrogen), and cDNA was generated from 1000 ng of total RNA,
using a High Capacity cDNA Reverse Transcription Kit (Applied
BioSystems/ABI). RT-PCR assays were performed on a QuantStudio™ 7
Flex Real-Time PCR system (Applied Biosystems) using SYBR Green
MasterMix (ABI). For accurate normalization of quantitative data, mul-
tiple housekeeping genes, including GAPDH, GUSB (glucuronidase-
beta) and UBC (polyubiquitin) were assayed. The primer sequences
used in RT-PCR assays are listed in the Key Resources Table.
2.9. Immunoprecipitation
Cells were washed with PBS and lysed in RIPA buffer containing NP-
40 and protease inhibitors (Roche). The lysate was cleared by centrifu-
gation at 13,000 Rcf for 30 min at 4 °C. Immunoprecipitation was per-
formed by incubation of cell lysates with anti-Flag or anti-HA
antibody, and capture on Dynabeads® Protein G (10003D, Thermo
Fisher Scientific) for 4 h at 4 °C in a rocking incubator. After six washes
with washing buffer, immunoprecipitated complexes were eluted in
sample buffer by boiling in water for 4 min, electrophoresed through
4–12% NuPAGE (Invitrogen) gel, and subjected to immunoblot analysis.
2.10. Determination of cell viability by MTS assay
Cell viabilities were assessed by adding MTS reagent,
3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (Biovision), to the cells. Optical density
was measured on a SpectraMax M2 microplate reader (Molecular De-
vices) at 490 nm. Each experiment was conducted in triplicate and re-
peated independently three times.
2.11. Luciferase reporter assay
Six copies of the antioxidant response element (ARE) (5′-GTGACA
AAGCACCCGTGACAAAGCACCCGTGACAAAGCACCCGTGACAAAGCACCC
GTGACAAAGCACCCGTGACAAAGCA-3′) were cloned into the pGL3-
basic luciferase reporter plasmid [27]. The indicated cells were
transfected with ARE-luciferase reporter and Renilla luciferase together
with either FAM129B plasmids or si-FAM129B. At 48–72 h after trans-
fection, the luciferase activities of cell lysates were measured with the
Dual Luciferase assay system (Promega).
2.12. GSH/GSSG detection
The ratio of reduced to oxidized glutathione (GSH/GSSG) in cellswas
measured using the GSH/GSSG-Glo™ Assay according to the manufac-
turer's instructions (Promega, V6611).
2.13. FLIM-FRET measurement
FLIM-FRET measurements were made as previously described [28],
withmodifications. A Leica TCS SP5 equippedwithmultiphoton fluores-
cence lifetime imaging microscopy (Leica TCS-SP5-AOBS-MP) system
was used for confocal imaging and to measure fluorescence lifetime. A
water immersion objective (Leica, 63×/0.9 APO) was employed both
for focusing laser light onto the samples and for collecting fluorescence
emissions from the samples. The fluorescence lifetime for each image
pixel was recorded using the time-correlated single photon counting
technique (Becker & Hickl SPEC-830 TCSPC modules).
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Interaction between Keap1 and FAM129Bwere assessed using an
in situ PLA kit (Duolink) according to the manufacturer's instructions.
In brief, cells (2 × 104) grown on 8-well slides (ibidi) were fixed in
4% paraformaldehyde in PBS for 15 min at room temperature,
blocked with Duolink blocking solution for 30 min at 37 °C, washed
with PBS, incubated overnight at 4 °C with primary antibodies (Rab-
bit anti-FAM129B and mouse anti-Keap1, as described above),ba
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Fig. 1. Identification of FAM129B as a Keap1-Interacting Protein. (a) Determination of interac
expressing Flag-FAM129B and HA-Keap1 were immunoprecipitated with anti-HA or an
immunoblotting with anti-Flag and anti-HA antibodies for detecting FAM129B and Keap1, res
transfected with AcGFP1-FAM129B and DsRed2-Keap1 expression constructs, and observe
FAM129B and red Keap1 molecules by a shift to orange. (c) FLIM-FRET measurements of the
AcGFP1-FAM129B constructs and DsRed2-Keap1. Fluorescence lifetime of AcGFP1 was dete
combination with DsRed2-Keap1. (left panels) Pictorial representations of the AcGFP1 lifetim
(right panels) Lifetime data from each pixel of the image, plotted on a graph. (d) Demonstr
Hs578T and HCT116 cells as determined by in situ PLA using anti-FAM129B and anti-Keap1 a
images. Scale bar in (b-d), 20 μm. (e) Examination of the FAM129B-Keap1 interaction us
expressing Keap1 fused with AD of VP16, along with a construct expressing full-length
performance of the mammalian two-hybrid assay at 24 h post transfection. The firefly lucifera
mean values of triplicates ± SD.washed with PBS, incubated for 1 h at 37 °C with secondary antibody
(anti-mouse PLA-plus probe or anti-rabbit PLA-minus probe;
Duolink; dilution 1:50), washed twice (5 min each time) with
Duolink Wash buffer A, combined with Duolink ligation mixture, in-
cubated for 30 min at 37 °C, washed twice with Wash buffer A, com-
bined with Duolink amplification mixture and Polymerase, subjected
to amplification reaction for 100 min at 37 °C, washed twice with
Wash buffer B and once with 0.1× Wash buffer B, and mounted
with Duolink In Situ Mounting Medium with DAPI [29]. Fluorescenced
e
AD AD-Keap1
Hs578T HCT116
FAM129B-Keap1 FAM129B-Keap1
Proximity ligation assay
P1-FAM129B DsRed-Keap1 Merge
tion between FAM129B and Keap1 by co-immunoprecipitation. Lysates of 293T cells co-
ti-Flag antibodies. The total lysates and the immunoprecipitates were subjected to
pectively. (b) Examination of co-localization of FAM129B and Keap1. 293T cells were co-
d under a confocal microscope. Overlay images demonstrate co-localization of green
FAM129B-Keap1 interaction by determination of fluorescence lifetime of FRET between
rmined in 293T cells 48 h after transfection with either AcGFP1-FAM129B alone or in
e; the color of the cell corresponds with the lifetime, which ranged from 2.1 to 2.8 ns.
ation of interaction between FAM129B and Keap1 by proximity ligation assay (PLA) in
ntibodies. Co-localization of FAM129B and Keap1 is reflected by red fluorescence in the
ing a mammalian two-hybrid assay. 293T cells were co-transfected with a construct
FAM129B fused with the DBD of GAL4 and the pG5 luciferase reporter, followed by
se activities were normalized to Renilla luciferase activities. The data are presented as the
29K.-C. Cheng et al. / EBioMedicine 45 (2019) 25–38dot images were obtained by confocal immunofluorescence micros-
copy as above.
2.15. Mammalian Two-Hybrid System
Interaction between Keap1 and FAM129B were assessed using a
CheckMate™ Mammalian Two-Hybrid System (Promega, E2440) ac-
cording to the manufacturer's instructions.
2.16. Statistical analyses
The prognostic performance of genes was calculated as mean
values. Relapse-free survival (RFS) values were estimated by the
Kaplan–Meier method and were compared by the log-rank test. The
Cox regression model was used for analysis of factors potentially re-
lated to RFS. The statistical analyses were performed with GraphPad
Prism software (version 5.0, GraphPad Software) and MedCalca b
c
e f
Fig. 2. FAM129B Interacts with the Kelch domain of Keap1 via its DLG and ETGE motifs. (a) Ex
different domains of Keap1, including anN-terminal region (amino acids 1–76), a BTB domain (a
327–611) and a Kelch/C domain (amino acids 327–624) were cloned and fused with the AD of
VP16, alongwith a construct expressing full-length FAM129B fusedwith theDBDofGAL4 and th
24 h post transfection. The firefly luciferase activities were normalized to Renilla luciferase acti
Keap1 interacting motifs (DLG and ETGE motifs; black lines) of FAM129B homologs in variou
partial conservation, respectively. (c) Predicted interactions of the Kelch domain with the DLG
725). Both motifs can access the same binding site on Kelch domain. (d) Predicted hydrogen b
motif of the FAM129B for binding with the Kelch domain. The radiating spokes represent
interactions near the ETGE motif involve more hydrogen bonds than DLG motif as shown in
ETGE motif by mammalian two-hybrid assay. Three FAM129B mutants, M1, M2 and M3, w
replaced with alanine residues. The data are presented as the mean values of triplicates ± SD
Keap1. 293T cell lysates co-expressing wild type (WT) or mutant Flag-FAM129B and HA
immunoprecipitates were subjected to immunoblot analysis with both anti-Flag and anti-HA astatistical software (version 14.8, MedCalc Software). Data are pre-
sented as means ±standard deviation (SD). Student's t-test was ap-
plied to assess the statistical significance. p-Values b.05 were
considered significant.
2.17. Ubiquitination assay
Cellswere exposed to 10 μMMG132 (Sigma) for 4 h. Cellswere lysed
by boiling in a buffer containing 2% SDS, 150 mMNaCl, 10 mM Tris-HCl
with 2 mM sodium orthovanadate, 50 mM sodium fluoride, and prote-
ase inhibitors. The lysates were incubated with an Nrf2 antibody and
subjected to immunoblot analysis.
2.18. Protein half-life measurement
Fifty micromolar cycloheximide (Sigma) was added in MDA-MB-
231 cells. Total cell lysates were collected at different time points andd
g
amination of FAM129B-Keap1 domain interactions by mammalian two-hybrid assay. Five
mino acids 77–179), a BACKdomain (amino acids 180–326), a Kelch domain (amino acids
VP16. 293T cells were co-transfected with a construct expressing Keap1 fused with AD of
e pG5 luciferase reporter, followed by performance of themammalian two-hybrid assay at
vities. The data are presented as the mean values of triplicates ± SD. (b) Alignment of the
s species. Black and grey boxes indicate identical amino acid residues with complete and
or the ETGE motif of the FAM129B peptide segment (705-KAVDLGPPKPSDQETGEQVSS-
onds (green dashed lines) and hydrophobic interactions (radiating spokes) near the DLG
the atoms or amino acid residues that have hydrophobic interactions. (e) Molecular
(d). (f) Examination of FAM129B-Keap1interaction through the FAM129B DLG motif or
ere generated, in which the indicated amino acids in the DLG and/or ETGE motif were
. (g) Effects of mutations of the DLG and ETGE motifs of FAM129B on its interaction with
-Keap1 were immunoprecipitated with anti-Flag antibody. The total lysates and the
ntibodies for detection of FAM129B and Keap1.
30 K.-C. Cheng et al. / EBioMedicine 45 (2019) 25–38subjected to immunoblot analysis with an anti-Nrf2 antibody. The rela-
tive intensities of the bands were quantified by using the ImageQuant
5.2 software.
3. Results
3.1. Identification of FAM129B as a Keap1-interacting protein
In a global proteomic analysis of 75 deubiquitinating enzymes [30]
and a proteomic analysis of Keap1 associated proteins [31], FAM129B
was listed as a potential candidate interacting protein for Keap1 by
mass spectrometry. In this study, we performed a series of experiments
to verify this association. First, 293T cells were co-transfectedwith Flag-
FAM129B and HA-Keap1, followed by reciprocal immunoprecipitation
experiments. As shown in Fig. 1a, HA-Keap1was present in the Flag im-
munoprecipitates and Flag-FAM129B was detected in the HA immuno-
precipitates, indicating that FAM129B and Keap1 were both present in
the same complex. Next, fluorescence microscopy was used to deter-
mine whether FAM129B and Keap1 co-localized in mammalian cells.
FAM129B and Keap1 were individually tagged with AcGFP1 and
DsRed2, respectively. AcGFP1-FAM129B and DsRed2-Keap1 proteinsd
ba
e f
Fig. 3. FAM129B Dampens the Keap1-Dependent Ubiquitination of Nrf2 by Competing with N
domains, while the C-terminal Kelch domains interact with Nrf2 protein. One Kelch domain
dimer might recruit FAM129B through binding to its DLG and ETGE motifs. (b) Competition b
293T cells were immunoprecipitated with anti-HA antibody. The resulting immunoprecipitate
recombinant protein, and then immunoblotted with the indicated antibodies. (c) Effects of F
the indicated plasmids followed by treatment with MG132 (10 μM) for 4 h. Cell lysates we
protein. Lysates were denatured and immunoprecipitated with anti-Nrf2 antibody and blot
antibodies. (d) Effects of FAM129B silencing on the stability of Nrf2 protein. MDA-MB-231 ce
were treated with cycloheximide (CHX), and cell lysates were harvested at the indicated time
normalized to β-actin, and the control group was set as 1. (e) Effects of FAM129B silencing o
pooled FAM129B-siRNAs (F). Cell lysates were collected at 72 h post transfection and sub
overexpression on the expression of Nrf2 protein. Cells were transfected with either empty ve
to immunoblot analyses using the indicated antibodies. (g) Effects of FAM129B silencing on t
siRNA (C) or pooled FAM129B-siRNAs (F). Cell lysates were collected at 72 h post transfectionwere co-expressed in 293T cells, and their cellular localizationwas visu-
alized by real-time live imaging system under a fluorescentmicroscope.
As shown in Fig. 1b, ectopically expressed AcGFP1-FAM129B and
DsRED2-Keap1 co-localized mainly in the cytoplasm (Pearson's
Correlation = 0.9126). To further validate their interactions, we mea-
sured Förster resonance energy transfer (FRET) of AcGFP1 using multi-
photon fluorescence lifetime imaging microscopy (FLIM). The
fluorescence lifetime (t1/2) of cells expressing AcGFP1-FAM129B
alone was distributed around 2.72 ns. Co-expression of DsRed2-Keap1
with AcGFP1-FAM129B produced a substantial shift in the distribution
of AcGFP1t1/2 to 2.57 ns (Fig. 1c). The shorter t1/2 is indicative of FRET
interaction between AcGFP1-FAM129B and DsRed2-Keap1. This finding
is further supported by the demonstration of in situ interactions be-
tween FAM129B and Keap1 using the proximity ligation assay (PLA).
With this method, when a pair of PLA probes binds two molecules in
close proximity (b 16 nm), complementary DNA strands conjugated to
PLA probes are ligated, amplified, and visualized as distinct points
using a fluorescent probe [29]. In both Hs578T and HCT116 cells, strong
PLA signalswere observed for the FAM129B-Keap1 association (Fig. 1d).
Moreover, a mammalian two-hybrid analysis was carried out in 293T
cells. FAM129B was fused to the DNA-binding domain (DBD) of GAL4,c
g
rf2 for Keap1 Binding. (a) Keap1 proteins form a homodimer through the N-terminal BTB
recognizes the DLG motif and the other binds the ETGE motif of Nrf2. Similarly, Keap1
etween Nrf2 and FAM129B for binding to Keap1. Cell lysates from HA-Keap1 expressing
s were co-incubated with Nrf2 recombinant protein and increasing amounts of FAM129B
AM129B overexpression on the ubiquitination of Nrf2. 293T cells were transfected with
re subjected to an in vivo ubiquitination assay to detect the ubiquitin-conjugated Nrf2
ted with anti-HA antibody. An aliquot of total lysate was analyzed using the indicated
lls were transfected with either control-siRNA or pooled FAM129B-siRNAs. At 72 h, cells
points for immunoblotting using the indicated antibodies. Nrf2 protein expression was
n the expression of Nrf2 protein. Cells were transfected with either control-siRNA (C) or
jected to immunoblot analyses using the indicated antibodies. (f) Effects of FAM129B
ctor or Flag-FAM129B. Cell lysates were collected at 48 h post transfection and subjected
he protein levels of Nrf2 downstream genes. Cells were transfected with either control-
and subjected to immunoblot analyses using the indicated antibodies.
Fig. 4.Nrf2 Antioxidative Signaling is Required for FAM129B to Inhibit ROS. (a) Effects of FAM129B silencing on ROS. At 72 h after transfectionwith the indicated siRNAs, intracellular ROS
levels were measured by using a DCF/flow cytometric method. (b) Efficiency of FAM129B silencing by pooled FAM129B-siRNAs. Cells were transfected with control-siRNA (C) or pooled
FAM129B-siRNAs (F). Cell lysates were collected at 72 h post transfection and subjected to immunoblot analyses using the indicated antibodies. (c) Effects of FAM129B silencing on the
GSH/GSSG ratio. Cellular oxidative statuswas determined bymeasuring the GSH/GSSG ratio after siRNA-mediated FAM129B knockdown. Fold changes inGSH/GSSG ratio are presented as
themean values of triplicates± SD. (d, e) Regulation of the ARE-reporter gene activity of Nrf2 by FAM129B. HCT116 cells were transfectedwith the indicated siRNAs (d) or constructs (e),
along with the expression vector for 6 repeats of the ARE element of the firefly luciferase promoter and Renilla luciferase. The firefly luciferase activities were normalized to Renilla
luciferase activities. The data are presented as the mean values of triplicates ± SD. ⁎p b .05, ⁎⁎⁎p b .001 (Student's t-test). (f) Effects of FAM129B silencing on the mRNA expression of
Nrf2 and its downstream genes. Cells were transfected with the indicated siRNAs. After 72 h, mRNAwas extracted for determination of the expression levels of Nrf2 and its downstream
genes by real-time RT-PCR. Values were normalized to GAPDH. The data are presented as the mean values of triplicates ± SD. (g) Effects of FAM129B overexpression on the mRNA ex-
pression of Nrf2 and its downstream genes. Cells were transfected with either empty vector or flag-FAM129B. At 48 h, mRNA was extracted for determination of the expression levels
of Nrf2 and its downstream genes by real-time RT-PCR. Values were normalized to GAPDH. The data are presented as the mean values of triplicates ± SD.
31K.-C. Cheng et al. / EBioMedicine 45 (2019) 25–38while Keap1 was fused to the activation domain (AD) of VP16. Activa-
tion of the GAL4/Luc reporter (pG5) was observed in cells co-
transfected with DBD-FAM129B and AD-Keap1 compared to cellstransfected with the DBD construct alone (Fig. 1e). Taken together,
these results validate that FAM129B and Keap1 can form a complex in
cells.
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33K.-C. Cheng et al. / EBioMedicine 45 (2019) 25–383.2. FAM129B interacts with the Kelch domain of Keap1 via its DLG and
ETGE motifs
To delineate which Keap1 domains contribute to the interaction
with FAM129B, we used mammalian two-hybrid assays to examine
the abilities of truncationmutants of different Keap1 domains, including
N, BTB, BACK, Kelch and Kelch/C, to bind FAM129B. We found that
FAM129B could only interactwithKeap1 truncationmutants containing
the Kelch domain (Fig. 2a). Previously, the Kelch domain of Keap1 was
reported to interact with the Neh2 domain of Nrf2 through its DLG
and ETGE motifs [32]. Interestingly, C-terminus of FAM129B also con-
tains DLG and ETGE motifs which were highly conserved in different
species (Fig. 2b). Although tertiary structure of FAM129B protein re-
mains unknown; we used computer modeling to predict binding of
human Kelch domain of Keap1 to a peptide fragment (K705–S725) of
FAM129B which covered the two motifs. Based on the structural infor-
mation of Kelch-Neh2 complex available from Protein Data Bank (see
EXPERIMENTEL MODEL), the DLG and the ETGE motifs of Nrf2 bound
separately to the same binding pocket located at Kelch domain of
Keap1via different orientation and molecular interactions. As shown
in Fig. 2c, our computer modeling predicted two orientations of
FAM129B K705–S725 peptide which could interact with the same
area of Kelch domain of human Keap1 through DLG motif (blue color)
and ETGEmotifs (red color). Moreover, the Hydrogen-bond analysis re-
vealed interactions between the Keap1-Kelch domain and FAM129B
K705–S725 peptide. The DLG motif of FAM129B peptide sequence
forms 5 hydrogen bonds (green-dashed lines in Fig. 2d) with the
amino acids on Keap1-Kelch domain. On the other hand, as many as
12 hydrogen bonds might occur near the ETGE motif of FAM129B pep-
tide sequence (Fig. 2e). We further assessed the binding energies of
the molecular interactions for these two binding modes using the
HotLig scoring program [24]. The estimated energy scores for the bind-
ing interactions through the DLG and the ETGE motifs were− 21.7 and
− 24.6, respectively. To further characterize the FAM129B-Keap1 inter-
action biochemically, three FAM129B mutants were created by alanine
replacement of amino-acid residues of its DLG and/or ETGE motifs. We
usedmammalian two-hybrid assays and co-immunoprecipitation to ex-
amine the binding abilities of the different FAM129Bmutants to Keap1.
The mammalian two-hybrid assays showed that mutation of either the
DLG or ETGE motif abolished binding to Keap1 (Fig. 2f). However, im-
munoprecipitation analysis revealed that mutation of the DLG motif
had a negligible effect on binding to Keap1, while mutation of the
ETGE motif abolished binding (Fig. 2g). The latter finding is consistent
with the reported lower binding affinity of the DLG motif ofNrf2 (1
× 106 M−1) for Keap1compared to the ETGE motif (2 × 108 M−1) [33].
These findings are also in agreement with our demonstration of higher
binding affinity of the ETGE motif of FAM129B than the DLG motif for
Keap1.
3.3. FAM129B Dampens the Keap1-dependent ubiquitination of Nrf2 by
competing with Nrf2 for Keap1 binding
The“hinge and latch”model has been proposed for Nrf2 stabilization
which involves high-affinity binding of ETGEmotif (hinge) to fix Nrf2 to
Keap1 and the low-affinity binding of DLG motif (latch) to lock down
theNeh2domain of Nrf2, thereby facilitating the ubiquitylation of lysineFig. 5. FAM129B Silencing Enhances Sensitivity of Cancer Cells to Oxaliplatin. (a,b) Sensitivity o
pooled FAM129B-siRNAs. At 72 h, cellswere treatedwith the indicated concentrations of tBHP fo
Cell viability was analyzed by MTS assay (b). The data are presented as the mean values of tri
silenced cells to oxaliplatin. Cells were transfected with control siRNA or pooled FAM129B-siR
and cell viability was analyzed byMTS assay. The data are presented as the mean values of trip
enhanced the suppressant effect of oxaliplatin on tumor growth. NSG mice (n= 4 each group
After 2 days, themicewere treatedwith PBS only or oxaliplatin. Tumor volumes at the indicated
(e). NOD/SCIDmice (n=5 each group) were injected subcutaneously with si-Control or si-FAM
with PBS only or oxaliplatin. Tumor volumes at the indicated time (f), and tumor images andwe
± SD. ⁎p b .05, ⁎⁎p b .01, ⁎⁎⁎p b .001 (one-way ANOVA with Tukey's multiple comparison test).residues and constant degradation of Nrf2 [32,33]. Since FAM129B in-
teracts with Keap1 through the same motif sequences (DLG and
ETGE) as Nrf2, the Keap1 dimer might also recruit FAM129B through
binding to its DLG and ETGE motifs, similar to the binding mode in-
volved in the Keap1-Nrf2 complex (Fig. 3a, right). In support of this no-
tion, in vitro binding experiments revealed that the amount of
recombinant Flag-Nrf2 protein forming a complex with HA-Keap1 de-
creased in proportion to the recombinant Flag-FAM129B protein level
(Fig. 3b). At the cellular level, FAM129B overexpression in 293T cells
led to a marked decrease in Nrf2 ubiquititylation (Fig. 3c). As expected,
the half-life of Nrf2was shorter in FAM129B-siRNA cells than in control-
siRNA cells (15.4 min versus 43.0 min) (Fig. 3d). In several cancer cell
lines, FAM129B silencing by siRNA reduced the expression of endoge-
nous FAM129B protein with a concomitant decrease in Nrf2 protein
levels (Fig. 3e). In contrast, overexpression of FAM129B increased Nrf2
protein levels (Fig. 3f). These results indicate that FAM129B interfered
with the Keap1-dependent ubiquitination of Nrf2 by competing with
Nrf2 for Keap1 binding.
3.4. Nrf2 antioxidative signaling is required for FAM129B to inhibit ROS
As the master antioxidant regulator, Nrf2 governs the intracellular
ROS level by regulating antioxidant gene products. Our findings that
FAM129B modulates the level of Nrf2 protein suggest the possibility of
involvement of FAM129B in regulating intracellular ROS. To address
this possibility, wemeasured ROS levels in control and FAM129B knock-
down cells, usingflow cytometry after stainingwith dichlorofluorescein
diacetate (DCF-DA). As shown in Fig. 4b, the expression of FAM129B
protein was effectively silenced by pooled FAM129B-siRNAs in MDA-
MB-231, Hs578T, HCT116 and H1299 cell lines. Interestingly,
FAM129B silencing was associated with elevated basal intracellular
ROS levels in these cells (Fig. 4a). As alterations in ROS levels can affect
the intracellular redox state, we measured the ratio of reduced to oxi-
dized glutathione (GSH/GSSG), which is a major indicator for oxidative
stress in cells [34]. As expected, the GSH/GSSG ratio was markedly
lowered in the FAM129B-siRNA-transfected cells (Fig. 4c). These results
suggest that FAM129B may ameliorate intracellular oxidative stress in
cancer cells.
To investigate the mechanisms underlying FAM129B-mediated ROS
inhibition, the relationship between FAM129B and Nrf2 signaling was
explored further. Nrf2 fulfills its function mainly by binding to the ARE
(antioxidant response element) region of antioxidant gene promoters
[35]. To investigate the effect of FAM129B on Nrf2 transcriptional activ-
ity, we used a luciferase reporter pGL3-ARE-luc to monitor the tran-
scriptional activity of Nrf2 in HCT116 cells. Under FAM129B
knockdown or overexpression conditions, the pGL3-ARE-luc activity
was significantly decreased by FAM129B knockdown to about 70% of
control values (Fig. 4d), but increased by about 3-fold by FAM129B
overexpression (Fig. 4e). To confirm above findings,we also determined
the mRNA levels of several Nrf2 downstream genes by real-time RT-
PCR, including AKR1B10 AKR1C1, AKR1C2, AKR1C3 and NQO1 [36]. In
general, FAM129B knockdown decreased the expression of most of
these Nrf2 downstream genes, whereas FAM129B overexpression in-
creased their levels in the two cell lines examined (Fig. 4f and g). The
protein levels of Nrf2 downstreamgenes, NQO1 andHO-1, were also re-
duced in FAN129B silenced cells (Fig. 3g). Furthermore, ectopicf FAM129B-silenced cells to oxidative stress. Cells were transfected with control siRNA or
r 24 h. Intracellular ROS levelsweremeasured by using a DCF/flow cytometricmethod (a).
plicates ± SD. ⁎p b .05, ⁎⁎p b .01, ⁎⁎⁎p b .001 (Student's t-test). (c) Sensitivity of FAM129B
NAs. At 72 h, cells were treated with the indicated concentrations of oxaliplatin for 48 h,
licates ± SD.⁎⁎p b .01, ⁎⁎⁎p b .001 (Student's t-test). (d–g) FAM129B silencing significantly
) were injected into mammary fat pad with si-Control or si-FAM129B MDA-MB-231 cells.
time (d), and tumor images andweights at day 35 after injection of tumor cells are shown
129B HCT116 cells. When the tumor sizes reached about 100mm3 themice were treated
ights at day 20 after injection of tumor cells are shown (g). Thedata are presented asmeans
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35K.-C. Cheng et al. / EBioMedicine 45 (2019) 25–38expression of Nrf2 reversed the increase in ROS induced by FAM129B
knockdown (Fig. S1a) and also rescued the reduction in the expression
Nrf2 downstream genes upon FAM129B silencing (Fig. S1b). Collec-
tively, these results further demonstrate that FAM129B inhibits ROS
production by enhancing the transcriptional activity of Nrf2 with the
consequent Nrf2-dependent antioxidant response.
3.5. FAM129B silencing enhances sensitivity of cancer cells to oxaliplatin
Our finding of the ability of FAM129B to stabilize Nrf2 protein im-
plies that FAM129B may contribute to antioxidant response. To deci-
pher the antioxidant function mediated by FAM129B, the effects of
tert-butyl hydroperoxide (tBHP), an organic peroxide, on ROS levels
and cell survival were determined. Treatment of FAM129B-siRNA-
transfected cells with tBHP further augmented ROS elevation as com-
pared to control-siRNA cells in each of the four cancer cell lines exam-
ined (Fig. 5a). FAM129B knockdown significantly increased the
susceptibility of these cell lines to tBHP-induced cell death (Fig. 5b).
These findings demonstrate that FAM129B has an antioxidant effect
that is required for cellular protection from oxidative stress.
Induction of ROS-mediated damage in cancer cells by pharmacolog-
ical agents such as platinum coordination compounds and
anthracyclines that either promote ROS generation or disable the cellu-
lar antioxidant system has been considered as an effective therapeutic
strategy to preferentially kill cancer cells [37]. In light of the antioxida-
tive activity of FAM129B, we further examined whether FAM129B si-
lencing would improve the response of cancer cells to the widely used
chemotherapeutic drug oxaliplatin. As expected, siRNA-mediated
FAM129B silencing significantly increased the sensitivity of MDA-MB-
231, Hs578T, andHCT116 cells to oxaliplatin (Fig. 5c). These findings in-
dicate that FAM129B depletion is a good strategy to augment the effi-
cacy of oxaliplatin in cancer therapy.
The in vivo effect of FAM129B on chemosensitivity was further ex-
amined using the MDA-MB-231 human breast cancer xenograft model
in severe combined immune-deficient NSG mice. As shown in Fig. 5d,
FAM129B knockdown did not suppress the tumor growth, in compari-
son to si-Controls (Fig. 5d and e). However, treatment with low dose
oxaliplatin had a significantly greater inhibitory effect, as assessed by
decreases in tumor volume, on si-FAM129B tumors than on si-
Controls (p b .01 [one-way ANOVA with Tukey's multiple comparison
test], Fig. 5d). Although oxaliplatin treatment had negligible effects on
tumor weight in si-Controls, it significantly reduced tumor weight in
the FAM129B knockdown group to 56% (p b .01 [one-way ANOVA
with Tukey's multiple comparison test]) of si-Controls (Fig. 5e). To fur-
ther confirm the role of FAM129B in chemosensitivity, a human colon
cancer xenograft model of HCT116 cells in severe combined immune-
deficient (NOD/SCID) mice was used. In contrast to results obtained
with the MDA-MB-231 xenograft model, FAM129B knockdown signifi-
cantly suppressed tumor growth, as compared to si-Controls (p b .05
[one-way ANOVA with Tukey's multiple comparison test], Fig. 5f).
Treatment of si-Controls with oxaliplatin also decreased tumor growth.
The combined inhibitory effect of FAM129B silencing and oxaliplatin
treatment on tumor growth was greater than the effect of oxaliplatin
alone (p b .05 [one-way ANOVA with Tukey's multiple comparison
test]) or FAM129B silencing alone (p b .01 [one-way ANOVA with
Tukey's multiple comparison test]). Furthermore, the average tumor
weight in the FAM129B knockdown group was 76% of the si-Control
group (p b .05 [one-way ANOVA with Tukey's multiple comparison
test], Fig. 5g) and treatment of the si-FAM129B group with oxaliplatinFig. 6. Elevated FAM129B expression correlates with expression of Nrf2 target genes and conf
adjacent normal tissues as determined by real-time RT-PCR and expressed in -Δ Ct, after
(b) Kaplan–Meier relapse-free survival (RFS) curves of 125 breast cancer patients stratified
Meier plots of relapse-free survival (RFS) and overall survival (OS) stratified by median FAM1
Meier plots of relapse-free survival (RFS) and overall survival (OS) stratified by quartile F
(g) Correlation analysis of the expression of FAM129B and Nrf2 downstream genes in TCGA-BRfurther reduced tumor weight to 27% (p b .001 [one-way ANOVA with
Tukey's multiple comparison test]) of si-Controls. In comparison,
oxaliplatin treatment of the si-Control group decreased tumor weight
tumor to 49% (p b .001 [one-wayANOVAwith Tukey'smultiple compar-
ison test]) of the untreated si-Controls (Fig. 5g). Collectively, these re-
sults indicate that FAM129B silencing rendered xenografts more
susceptible to oxaliplatin, showing a critical role of FAM129B in
chemosensitivity in vivo.
3.6. Elevated FAM129B expression correlates with expression of Nrf2 target
genes and confers poor clinical outcome
To investigate the clinical relevance of FAM129B in human cancers,
we determined FAM129B expression by RT-PCR in 126 breast cancer
specimens and their adjacent normal tissues. The clinicopathologic
characteristics of these patients are shown in Supplemental Table S1.
FAM129B expression was significantly higher in tumor than the adja-
cent normal tissue (p b .0001 [Paired t-test], Fig. 6a). More importantly,
Kaplan–Meier survival analysis showed that patients with greater than
mean expression levels of FAM129B had significantly worse relapse-
free survival (RFS) than those with lower FAM129B expression (p =
.0206 [Log-rank test], Fig. 6b). Univariate Cox proportional hazard re-
gression analyses were conducted. RFS correlated with age, ER negative
status, advanced stage (stage III and IV), triple negative molecular type
and high FAM129B expression (Table 1). The statistically significant fac-
tors for RFS that were identified using multivariate analyses are also
presented in Table1. Advanced stage (stage III and IV), triple negative
molecular type, and high FAM129B expression were identified as inde-
pendent predictors of tumor recurrence (Table 1). These results suggest
that in addition to the well-known negative impact of “clinical stage”
and “triple-negative molecular type”, high FAM129B gene expression
can serve as a prognostic marker for tumor recurrence (hazard ratio
1.967, 95% CI, 1.065–3.632). To further validate the prognostic value of
FAM129B, we applied GEPIA (Gene Expression Profiling Interactive
Analysis; http://gepia.cancer-pku.cn), for survival analysis of web-
based TCGA (The Cancer GenomeAtlas) cancer gene expression profiles
[38]. Consistentwith ourfindings, elevated FAM129was found to corre-
latewith poorer RFS in breast cancer (p b .001 [Log-rank test], Fig. 6c). In
addition, FAM129B overexpression had significant adverse impacts on
overall survival in breast cancer (p b .001 [Log-rank test], Fig. 6d), as
well as RFS (p b .01 [Log-rank test], Fig. 6e) and overall survival (p b
.06 [Log-rank test], Fig. 6f) in lung cancer. Thus, FAM129B may serve
as a prognostic marker for clinical outcome of breast and lung cancer.
Finally, to establish the physiological role of FAM129B in controlling
Nrf2 transcriptional activity in breast and lung cancer, we examined
whether the expression of FAM129B correlated to Nrf2 downstream
genes. Using GEPIA analysis of TCGA database, we found FAM129B ex-
pression to be positively correlated with several Nrf2 downstream
genes including ABCC1, ACOT7, MAFG and PTGR1 [39,40] in breast
and lung cancer (Fig. 6g). These data support the notion that high
FAM129B expression in tumors can upregulate their Nrf2 activities.
4. Discussion
In this report, we have provided the first evidence that FAM129B
plays an important role in regulating the antioxidant capacity of cancer
cells via stabilization of Nrf2 protein by competing with Nrf2 for Keap1
binding through both theDLG and ETGEmotifs of FAM129B as shown in
the schematic diagram (Fig. 7). We also demonstrate that highers poor clinical outcome. (a) FAM129B mRNA levels in paired human breast tumor and
subtracting the average of 3 reference genes, GAPDH, GUSB and UBC. (Paired t-test).
by mean FAM129B mRNA levels in their tumor samples. (Log-rank test). (c, d) Kaplan–
29B expression in TCGA-BRAC (breast invasive carcinoma). (Log-rank test). (e, f) Kaplan–
AM129B expression in TCGA-LUSC (lung squamous cell carcinoma). (Log-rank test).
AC and TCGA-LUSC expression profiles. (Spearman rank correlation test).
Table 1
Univariate and multivariate analyses of factors associated with relapse-free survival.
Clinical variable Univariate analysisa Multivariate analysisb
Hazard ratio (95% CI)c p value Hazard ratio (95% CI) p value
Age (years) 1.0220 (1.0007–1.0438) 0.0435
ER (negative vs positive) 0.4787 (0.2618–0.8753) 0.0173
PR (negative vs positive) 0.5903 (0.3229–1.0789) 0.0883
HER-2 (negative vs positive) 0.6637 (0.3631–1.2130) 0.185
Stage (I + II vs III + IV) 2.5809 (1.3829–4.8617) 0.003 2.8646 (1.5162–5.4125) 0.0013
Subtype
Luminal A vs Luminal B 0.8782 (0.4194–1.8388) 0.7318
Luminal A vs HER2 positive 0.7136 (0.2381–2.1386) 0.5489
Luminal A vs Triple negative 2.8099 (1.2908–6.1166) 0.0096 3.2317 (1.5868–6.5816) 0.0013
FAM129B (low vs high) 2.0030 (1.1026–3.6388) 0.0233 1.9674 (1.0655–3.6327) 0.0314
The bold indicate the numbers p values that are statistically significant.
a Univariate analysis, Cox proportional hazards regression.
b Multivariate analysis, Cox proportional hazards regression.
c 95%CI: 95% confidence interval.
36 K.-C. Cheng et al. / EBioMedicine 45 (2019) 25–38expression of FAM129B is associatedwith chemosensitivity and adverse
clinical outcome of breast cancer and possibly other types of cancer.
It has been shown that the unique association mechanism between
Nrf2 and Keap1 involves two Keap1 molecules interacting with one
Nrf2 molecule through its DLG and ETGE motifs. This two-site binding
facilitates the ubiquitylation and degradation of Nrf2 [32,33]. A hingeFig. 7. A schematic diagram of regulation of Nrf2 activity by FAM129B in cancer cells. The sch
FAM129B in cancer promotes Nrf2 activity by reducing its ubiquitination through compet
activation of Nrf2 to drive downstream antioxidant genes, which ultimately suppresses ROS prand latch model was proposed as the stress-sensing mechanism, in
which the low-affinity DLG motif acts as a latch for turning the
ubiquitylation of Nrf2 on or off [32]. Furthermore, a recent study pro-
posed that the Keap1-Nrf2 complex is in dynamic flux. In cells, the
open” conformation, in which Nrf2 binds with Keap1 via the DLG
motif only, coexists with the “closed” conformation, in which Nrf2ema illustrates how FAM129B modulates ROS and chemosensitivity. Overexpression of
ition with Nrf2 for Keap1 binding, allowing nuclear translocation and transcriptional
oduction and reduces chemosensitivity.
37K.-C. Cheng et al. / EBioMedicine 45 (2019) 25–38binds with Keap1 via both the DLG and ETGE motifs. Cycling from an
open to a closed conformation allows ubiquitination and degradation
of Nrf2 with subsequent regeneration of free Keap1 [41,42]. As
discussed above, FAM129B may interfere with the dynamics of the
Keap1-Nrf2 complex, leading to insufficient free Keap1 for binding
Nrf2. Thus, de novo-synthesized Nrf2 will be free to translocate to the
nucleus for activation of downstream genes. In addition, recent studies
have identified six proteins, p21, p62, WTX, PALB2, DPP3, and iASPP
that bind Keap1 or Nrf2 and, thereby, inhibit Nrf2 ubiquitination
[31,42–46]. Of these, WTX, PALB2, and DPP3 employ an ETGE motif to
bind Keap1 directly, thus displacing and stabilizing Nrf2. Unlike most
of the Keap1-Nrf2 complex disruptor proteins, FAM129B contains
both ETGE and DLG motifs. Therefore, FAM129B may interfere with
the binding of Nrf2 to Keap1 more efficiently than proteins containing
an ETGE motif only.
The Nrf2-Keap1 antioxidant response pathway plays a crucial role in
chemoprevention and cancer therapy. High levels of Nrf2 protein in
cancer cells confer resistance to chemotherapeutic drugs such as cis-
platin, doxorubicin and etoposide [47,48].The effector function of Nrf2
may contribute to chemotherapy resistance by several mechanisms:
1) suppression of oxidative stress, which is an important aspect of the
cytotoxicity of chemotherapy; 2) drug detoxification by glutathione
and other conjugating mechanisms; 3) transcriptional up-regulation
of the multidrug resistance genes, which can lower effective drug con-
centrations [49]. In view of the high frequency of tumors displaying
Nrf2 hyperactivation, Nrf2 has been considered as a potential pharma-
cological target. Unfortunately, it has been difficult to develop specific
and effective Nrf2 inhibitors since Nrf2 belongs to a big family of basic
leucine zipper transcription factors,which are involved in the regulation
of diverse and critical biological functions [42,50]. On the other hand, fo-
cusing on uncovering Nrf2 regulatory mechanisms via protein-protein
interactions may provide an alternative to inhibit Nrf2 directly. Our
finding that FAM129B-silencing enhanced the sensitivity of cancer
cells to oxaliplatin provided an additional mechanism of Nrf2-
associated drug resistance through competition between FAM129B
andNrf2 for Keap1 binding. Thus, FAM129B is an attractive target, espe-
cially in view of our findings of higher FAM129B levels in many cancers,
as compared to their normal tissue counterparts. These findings suggest
that FAM129B depletion may be considered as a novel strategy for im-
proving treatment outcome in cancers.
In our xenograft models, FAM129B silencing rendered xenografts
more susceptible to oxaliplatin, leading to reduction of tumor weight
and volume. We should point out that the gene silencing effect via
siRNAwill dwindle by 1 week. Since HCT116 andMDA-MB-231 tumors
were harvested on day 20 and 35 respectively, in our xenograft models,
we found no difference in the expression of level of Nrf2 and its down-
stream genes in HCT116 xenograft tumors between si-Control and si-
FAM129B group via real-time PCR (Fig. S2). This suggests that the im-
pacts of FAM129B on chemosensitivity must have occurred during the
initial week after silencing of FAM129B by siRNA approach.
Given the above findings that FAM129B contributes to Nrf2 stability
and reduces chemosensitivity, and the previous reports of pro-
tumorigenic activity of FAM129B, it is likely that FAM129B expression
level may influence patient outcome. Indeed, we demonstrated that
high expression of FAM129B was a poor prognostic factor for breast
cancer and lung cancer by examination of clinical specimens of breast
cancer and data mining. To our knowledge, this is the first report on
the prognostic significance of high expression of FAM129B. Further-
more, FAM129B expression positively associated with the expression
of NRF2 downstream genes, in line with our in vitro finding of stabiliza-
tion of Nrf2 by FAM129B. Since several cancer types have been found to
exhibit constitutive Nrf2 activation without genomic alterations in Nrf2
and Keap1, our data collectively support the notion that FAM129B may
not only provide a novel mechanism for promoting Nrf2 activation, but
also serve as a potential therapeutic target and prognosis factor formul-
tiple different cancer types.Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.06.022.
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